Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours

AIMS: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P‐glycoprotein (P‐gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)‐acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Faessel, Hélène, Nemunaitis, John, Bauer, Todd M., Lockhart, A. Craig, Faller, Douglas V., Sedarati, Farhad, Zhou, Xiaofei, Venkatakrishnan, Karthik, Harvey, R. Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595297/
https://www.ncbi.nlm.nih.gov/pubmed/30845347
http://dx.doi.org/10.1111/bcp.13915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595297/
https://www.ncbi.nlm.nih.gov/pubmed/30845347
http://dx.doi.org/10.1111/bcp.13915

Ejemplares similares